Serzone – Recent News
Created by FindLaw’s team[1] of legal writers and editors
| Last updated June 20, 2016
May 19, 2004: Bristol-Myers Squibb Announces U.S. Sales of Serzone to End in June
Bristol-Myers Squibb announced that Serzone will no longer be sold in the U.S. after June 14th, 2004. A company spokesperson indicated that this decision was made due to declining sales, not safety issues. Note that this action does not affect sales of generic versions of Serzone (nefazodone).
March 22, 2004: FDA Asks Antidepressant Manufacturers to Advise Observation of Patients
The U.S. Food and Drug Administration (FDA) issued a Public Health Advisory asking manufacturers of a number of anti-depressants (including Serzone, Prozac, Zoloft, Paxil, and more) to include in their product labeling a statement recommending close observation of adult and child users of the prescribed medication, for signs of increased depression and/or the emergence of suicidal impulses. Read the FDA’s Public Health Advisory here[2].
March 15, 2004: Public Citizen Group Sues FDA Over Failure to Ban Serzone
The consumer group Public Citizen sued the U.S. Food and Drug Administration (FDA) over its failure to act on the group’s petition seeking a ban on the antidepressant nefazodone, marketed as Serzone. The lawsuit asks the court to find the FDA’s failure to act illegal, and to require the agency to take regulatory action. Go here[3] to see the Public Citizen press release. Click here[4] to read the complaint filed by Public Citizen.
References
Source URL: Read More
The public content above was dynamically discovered – by graded relevancy to this site’s keyword domain name. Such discovery was by systematic attempts to filter for “Creative Commons“ re-use licensing and/or by Press Release distributions. “Source URL” states the content’s owner and/or publisher. When possible, this site references the content above to generate its value-add, the dynamic sentimental analysis below, which allows us to research global sentiments across a multitude of topics related to this site’s specific keyword domain name. Additionally, when possible, this site references the content above to provide on-demand (multilingual) translations and/or to power its “Read Article to Me” feature, which reads the content aloud to visitors. Where applicable, this site also auto-generates a “References” section, which appends the content above by listing all mentioned links. Views expressed in the content above are solely those of the author(s). We do not endorse, offer to sell, promote, recommend, or, otherwise, make any statement about the content above. We reference the content above for your “reading” entertainment purposes only. Review “DMCA & Terms”, at the bottom of this site, for terms of your access and use as well as for applicable DMCA take-down request.